Cascade Specialty Pharmacy, LLC — FDA Form 483

FDA FORM 483 • INSPECTIONAL OBSERVATIONS

Cascade Specialty Pharmacy, LLC — FDA Form 483: Key GMP Observations & Learning Points

Educational review of FDA inspectional observations, quality-system weaknesses, risk considerations and practical GMP lessons for pharmaceutical and compounding operations.

⚠️ Important Educational Notice

This page is provided for educational, professional-development and GMP awareness purposes only. The information presented is based on the FDA Form 483 document reviewed for this article.

A Form 483 contains inspectional observations and does not, by itself, represent a final FDA determination regarding compliance. The FDA Form 483 itself states that the observations are inspectional observations and not a final Agency determination.

PharmaceuticalMicrobiology.in does not criticize, condemn or make a compliance judgment about Cascade Specialty Pharmacy, LLC or its personnel. The purpose of this article is to help pharmaceutical professionals understand inspection observations and strengthen their own quality systems.

📋 FDA Inspection Information

Firm	Cascade Specialty Pharmacy, LLC
Location	Poulsbo, Washington
Inspection Dates	July 6–17, 2026
Document	FDA Form 483 — Inspectional Observations
Observations Reviewed	6 observations

🎯 Why Pharmaceutical Professionals Should Study FDA 483 Observations

FDA Form 483 observations can provide useful learning opportunities for pharmaceutical, quality, laboratory, manufacturing and compounding professionals.

The objective is not simply to identify what went wrong at another organization. The more valuable question is: “Could the same weakness exist in our own system?”

🔎 FDA Form 483 — Observation Summary

The reviewed FDA Form 483 contains six observations covering quality-unit responsibilities, batch documentation, cleaning and maintenance procedures, deactivation controls, finished-product testing, component identity testing and stability programs.

Observation 1 — Quality Control Responsibilities & Procedures

The FDA observation states that responsibilities and procedures applicable to the quality control unit were not fully followed.

The cited example concerned a compounding record that did not sufficiently specify the container and closure system for a Gabapentin suspension stock solution. The record reportedly stated only “Bottle with Insert and Dosing Syringe” without specifying the material or type of container.

GMP Learning Point:
Batch and compounding records should contain sufficient information to ensure that critical materials, components, containers and processing parameters are appropriately defined and consistently controlled.

Observation 2 — Batch Production & Control Records

The FDA observation states that batch production and control records did not include complete information relating to production and control of each batch.

Examples described in the document included insufficient instructions for tablet crushing or dissolving and inadequate instructions for transferring a product into a 1 mL syringe.

GMP Learning Point:
Critical processing parameters should be clearly defined so that a process can be performed consistently by different trained operators and the resulting product can be appropriately controlled.

Observation 3 — Cleaning, Maintenance & Deactivation Controls

The document states that written procedures were not established for cleaning and maintenance of equipment and utensils used in manufacture, processing, packing or holding of drug products.

The FDA observation also describes the absence of in-house efficacy data supporting the effectiveness and contact time of a deactivating agent for beta-lactam residue in the relevant non-dedicated work area.

GMP Learning Point:
Cleaning and deactivation programs should be scientifically justified, documented, implemented through controlled procedures and periodically assessed for effectiveness where applicable.

Observation 4 — Finished Product Identity & Strength Testing

The FDA observation states that testing and release of drug products did not include appropriate laboratory determination of satisfactory conformance to identity and strength of each active ingredient before release.

The document gives examples involving Trilostane capsules and Gabapentin suspension, where the cited finished products were not subjected to identity or strength testing before release as described in the observation.

GMP Learning Point:
Organizations should ensure that their release-testing strategy is appropriately defined, scientifically justified and capable of demonstrating conformance with applicable requirements.

Observation 5 — Component Identity Testing & Supplier Controls

The FDA observation states that specific identification tests were not conducted on components accepted based on supplier certificates of analysis.

The document identifies examples where components were accepted using supplier CoAs without identity testing and also states that the reliability of supplier CoAs had not been demonstrated through adequate validation or testing at appropriate intervals.

GMP Learning Point:
Supplier qualification, incoming material controls, identity verification and ongoing supplier-performance monitoring should be integrated into the quality system.

Observation 6 — Stability Testing & Beyond-Use Dating

The FDA observation states that there was no written testing program designed to assess stability characteristics of drug products.

The document further states that the firm did not have a written stability testing program to determine the beyond-use date for each drug product and describes the basis cited in the inspection for assigning beyond-use dates.

GMP Learning Point:
Stability programs and beyond-use-date decisions should be supported by an appropriately documented scientific and regulatory framework applicable to the product and operation.

🧠 What Can Other Pharmaceutical Organizations Learn?

1. Documentation

Ensure records contain sufficient detail to consistently execute critical operations.

2. Quality Unit

Verify that approved procedures are actually followed in routine operations.

3. Cleaning

Maintain scientifically justified cleaning and deactivation controls.

4. Laboratory Controls

Evaluate whether release testing adequately demonstrates product quality.

5. Supplier Controls

Do not rely on supplier documentation without an appropriate control strategy.

6. Stability

Ensure stability and dating decisions are appropriately documented and supported.

✅ Pharmaceutical GMP Self-Assessment Questions

Use the following questions as an internal awareness exercise:

• Do our batch and compounding records contain all critical processing parameters?
• Are container and closure systems adequately specified where relevant?
• Are cleaning and maintenance procedures established, approved and followed?
• Do we have scientific evidence supporting critical deactivation processes where required?
• Does our release-testing program adequately verify applicable identity and strength requirements?
• Are incoming components appropriately identified and controlled?
• How do we qualify and periodically evaluate supplier CoA reliability?
• Is our stability program sufficient to support applicable dating decisions?
• Can another trained operator reproduce the process using the approved record alone?
• Can our quality unit demonstrate that written procedures are consistently implemented?

🔧 CAPA & Root-Cause Thinking

When a similar observation is identified internally, organizations should avoid simply correcting the individual example. A robust investigation should determine whether the issue represents an isolated event or a broader system weakness.

Consider reviewing: people → procedures → process → materials → equipment → laboratory controls → documentation → training → management oversight → quality-system effectiveness.

The objective should be sustainable corrective and preventive action rather than a short-term correction that addresses only the inspection example.

📚 Explore More FDA Regulatory Resources

FDA 483s FDA Warning Letters FDA Guidance Pharmaceutical Microbiology Home

📌 Source & Document Note

This educational review is based on the FDA Form 483 document supplied for review. The document identifies Cascade Specialty Pharmacy, LLC, Poulsbo, Washington, and records an FDA inspection conducted from July 6–17, 2026.

The supplied document contains six inspectional observations. The FDA Form 483 also states that the observations do not represent a final Agency determination regarding compliance.

⚖️ Disclaimer

Educational Use Only: This article is intended solely for educational, training, GMP awareness and professional-development purposes.

No Criticism or Defamation: PharmaceuticalMicrobiology.in does not intend to criticize, accuse, defame or make a negative judgment about the company, its employees, management, products or operations discussed in this educational review.

FDA Form 483 Status: A Form 483 contains inspectional observations. It should not be presented as a final FDA enforcement determination or as proof of a company's overall compliance status.

No Legal or Regulatory Advice: This article is not legal advice, regulatory advice, compliance certification or a substitute for review of applicable laws, regulations, FDA communications, official guidance or professional advice.

Readers should consult the original FDA documents and applicable regulatory requirements before making compliance decisions.

PharmaceuticalMicrobiology.in

FDA 483s • FDA Warning Letters • FDA Guidance • GMP • Pharmaceutical Microbiology

Home Disclaimer